Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.430
-0.040 (-1.62%)
At close: Jul 20, 2026, 4:00 PM EDT
2.440
+0.010 (0.41%)
After-hours: Jul 20, 2026, 7:34 PM EDT
Grace Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Grace Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $6.02. The average 1-year stock price forecast is 147.74% higher than the current stock price, while the lowest is $4.04 (+66.26%) and the highest is $7.99 (+228.81%).
Price Target: $6.02 (+147.74%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Apr 23, 2026.
Analyst Ratings
The average analyst rating for Grace Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Aug '25 | Nov '25 | Feb '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $12 → $8 | Buy | Reiterates | $12 → $8 | +229.22% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
5.58M
EPS This Year
-0.53
from -0.47
EPS Next Year
-0.55
from -0.53
EPS and Forward PE are based on non-GAAP adjusted numbers.